Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Gynecologic 2Genitourinary 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Other 1Myeloid 1Head & Neck 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Lymphoma, Follicular 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Renal Insufficiency 1Pancreatic Neoplasms 1Lymphoma, B-Cell 1Lung Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Rituximab 1401Cyclophosphamide 1305Vincristine 668Doxorubicin 587Etoposide 527Prednisone 510Cytarabine 486fludarabine 469Methotrexate 445Dexamethasone 413fludarabine phosphate 400Lenalidomide 356Filgrastim 343Bendamustine Hydrochloride 282Radiotherapy 267venetoclax 260ibrutinib 258obinutuzumab 235Peripheral Blood Stem Cell Transplantation 234Melphalan 230Granulocyte Colony-Stimulating Factor 215Bortezomib 204Gemcitabine 202Busulfan 188Whole-Body Irradiation 187Mycophenolic Acid 175Tacrolimus 165Specimen Handling 162Magnetic Resonance Spectroscopy 155Calcium Dobesilate 150

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
mirabegron × Lymphoid × Clear all
NCT06534762 2024-08-02

Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study

Zhejiang Provincial People's Hospital

Phase 2 Recruiting
260 enrolled
BreastGastrointestinalHead & NeckLymphoidSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Lymphoma, B-Cell, Dendritic Cell Sarcoma, Interdigitating, Triple Negative Breast Neoplasms

NCT00750620 2013-09-05

A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment

Astellas Pharma Inc

Phase 1 Completed
33 enrolled
Lymphoid

Lymphoma, Follicular, Renal Insufficiency

NCT01579461 2013-09-05

A Study to Investigate the Effect of Mirabegron (YM178) on Subjects With Mild or Moderate Hepatic Impairment Compared to Healthy Subjects

Astellas Pharma Inc

Phase 1 Completed
32 enrolled
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡